Eli Lilly initiates LIBRETTO-531 phase III clinical trial for LOXO 292 to treat RET-mutant medullary thyroid cancer.
Related news and insights
CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China has approved the supplemental new drug application (sNDA) of selective RET inhibitor Gavreto (pralsetinib) for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC).
Genentech, a member of the Roche Group announced that the FDA has approved Gavret (pralsetinib) for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Blueprint Medicines announced the FDA has accepted the company's new drug application (NDA) for pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.